vs
Side-by-side financial comparison of BEYOND MEAT, INC. (BYND) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $61.6M, roughly 1.4× BEYOND MEAT, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -19.7%). BEYOND MEAT, INC. produced more free cash flow last quarter ($-49.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -9.7%).
Beyond Meat, Inc., branded as Beyond, is a producer of plant-based meat alternatives founded in 2009 by Ethan Brown. The company's products were first launched in the United States in 2012.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BYND vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.6M | $86.8M |
| Net Profit | — | — |
| Gross Margin | -11.5% | 67.4% |
| Operating Margin | -211.4% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | -19.7% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.68 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.6M | $86.8M | ||
| Q3 25 | $70.2M | $67.5M | ||
| Q2 25 | $75.0M | $60.0M | ||
| Q1 25 | $68.7M | $49.3M | ||
| Q4 24 | $76.7M | $73.7M | ||
| Q3 24 | $81.0M | $58.6M | ||
| Q2 24 | $93.2M | $31.1M | ||
| Q1 24 | $75.6M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-110.7M | $-91.3M | ||
| Q2 25 | $-29.2M | $-111.7M | ||
| Q1 25 | $-52.9M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-26.6M | $-83.5M | ||
| Q2 24 | $-34.5M | $-97.1M | ||
| Q1 24 | $-54.4M | $-113.0M |
| Q4 25 | -11.5% | 67.4% | ||
| Q3 25 | 10.3% | 43.0% | ||
| Q2 25 | 11.5% | 5.5% | ||
| Q1 25 | -1.5% | -0.8% | ||
| Q4 24 | 13.1% | 68.7% | ||
| Q3 24 | 17.7% | 46.2% | ||
| Q2 24 | 14.7% | -0.8% | ||
| Q1 24 | 4.9% | — |
| Q4 25 | -211.4% | -84.7% | ||
| Q3 25 | -160.0% | -140.7% | ||
| Q2 25 | -46.6% | -189.8% | ||
| Q1 25 | -81.8% | -245.8% | ||
| Q4 24 | -49.3% | -117.5% | ||
| Q3 24 | -38.2% | -152.1% | ||
| Q2 24 | -36.4% | -327.6% | ||
| Q1 24 | -70.7% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | -157.6% | -135.3% | ||
| Q2 25 | -39.0% | -186.2% | ||
| Q1 25 | -77.0% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -32.8% | -142.7% | ||
| Q2 24 | -37.0% | -312.2% | ||
| Q1 24 | -71.9% | -15800.8% |
| Q4 25 | $0.68 | — | ||
| Q3 25 | $-1.44 | — | ||
| Q2 25 | $-0.38 | $-0.33 | ||
| Q1 25 | $-0.69 | $-0.36 | ||
| Q4 24 | $-0.65 | $-0.24 | ||
| Q3 24 | $-0.41 | $-0.28 | ||
| Q2 24 | $-0.53 | $-0.34 | ||
| Q1 24 | $-0.84 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.9M | $297.0M |
| Total DebtLower is stronger | $415.7M | — |
| Stockholders' EquityBook value | $-997.0K | $698.6M |
| Total Assets | $614.7M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.9M | $297.0M | ||
| Q3 25 | $117.3M | $300.8M | ||
| Q2 25 | $103.5M | $301.2M | ||
| Q1 25 | $102.1M | $359.7M | ||
| Q4 24 | $131.9M | $323.8M | ||
| Q3 24 | $121.7M | $397.5M | ||
| Q2 24 | $144.9M | $412.5M | ||
| Q1 24 | $157.9M | $356.2M |
| Q4 25 | $415.7M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $-997.0K | $698.6M | ||
| Q3 25 | $-784.1M | $702.3M | ||
| Q2 25 | $-677.0M | $698.5M | ||
| Q1 25 | $-649.5M | $767.9M | ||
| Q4 24 | $-601.2M | $710.4M | ||
| Q3 24 | $-611.9M | $773.5M | ||
| Q2 24 | $-590.0M | $768.5M | ||
| Q1 24 | $-561.4M | $680.0M |
| Q4 25 | $614.7M | $913.2M | ||
| Q3 25 | $599.7M | $904.9M | ||
| Q2 25 | $691.7M | $907.4M | ||
| Q1 25 | $643.8M | $966.7M | ||
| Q4 24 | $678.1M | $910.4M | ||
| Q3 24 | $692.9M | $991.1M | ||
| Q2 24 | $711.2M | $964.3M | ||
| Q1 24 | $735.0M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.8M | $-52.6M |
| Free Cash FlowOCF − Capex | $-49.8M | $-61.9M |
| FCF MarginFCF / Revenue | -80.8% | -71.3% |
| Capex IntensityCapex / Revenue | 4.8% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-157.2M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.8M | $-52.6M | ||
| Q3 25 | $-38.8M | $-78.7M | ||
| Q2 25 | $-33.2M | $-67.4M | ||
| Q1 25 | $-26.1M | $-103.7M | ||
| Q4 24 | $-29.0M | $-73.3M | ||
| Q3 24 | $-22.0M | $-59.0M | ||
| Q2 24 | $-16.0M | $-98.4M | ||
| Q1 24 | $-31.8M | $-122.3M |
| Q4 25 | $-49.8M | $-61.9M | ||
| Q3 25 | $-41.7M | $-89.5M | ||
| Q2 25 | $-35.1M | $-74.9M | ||
| Q1 25 | $-30.6M | $-109.9M | ||
| Q4 24 | $-35.4M | $-77.5M | ||
| Q3 24 | $-24.1M | $-61.3M | ||
| Q2 24 | $-17.3M | $-98.9M | ||
| Q1 24 | $-33.0M | $-126.5M |
| Q4 25 | -80.8% | -71.3% | ||
| Q3 25 | -59.4% | -132.7% | ||
| Q2 25 | -46.9% | -124.9% | ||
| Q1 25 | -44.6% | -222.8% | ||
| Q4 24 | -46.2% | -105.1% | ||
| Q3 24 | -29.7% | -104.6% | ||
| Q2 24 | -18.6% | -317.9% | ||
| Q1 24 | -43.7% | -17685.3% |
| Q4 25 | 4.8% | 10.7% | ||
| Q3 25 | 4.1% | 16.1% | ||
| Q2 25 | 2.6% | 12.4% | ||
| Q1 25 | 6.5% | 12.6% | ||
| Q4 24 | 8.4% | 5.7% | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 1.6% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYND
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
